{"id":4247,"date":"2023-05-23T15:51:26","date_gmt":"2023-05-23T13:51:26","guid":{"rendered":"https:\/\/www.biopole-clermont.com\/?p=4247"},"modified":"2023-05-23T15:51:56","modified_gmt":"2023-05-23T13:51:56","slug":"valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete","status":"publish","type":"post","link":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/","title":{"rendered":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes."},"content":{"rendered":"<p>Valbiotis, a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the large success of the REVERSE-IT Phase II\/III clinical study on TOTUM\u202263.<\/p>\n<p>Conducted in 636 prediabetic and untreated type 2 diabetic patients (early stage), this international, multicentric, randomized and placebo-controlled study confirms the efficacy of TOTUM\u202263 in reducing fasting blood glucose at 2 and 3 intakes per day.<\/p>\n<p>The results of the REVERSE-IT study on TOTUM\u202263 represent a major breakthrough in the fight against diabetes and its complications for people with prediabetes and untreated type 2 diabetes (early stage), by providing unequivocal clinical evidence that TOTUM\u202263 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.<\/p>\n<p>These positive results trigger a lump sum payment of CHF 4 million from Nestl\u00e9 Health Science as part of the global strategic partnership. They also validate Valbiotis&#8217; scientific approach, based on the use of innovative and patented combinations of plant-based active ingredients for the prevention of metabolic and cardiovascular diseases.<\/p>\n<p><a href=\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/2023-05-22_PR_VALBIOTIS_T63_REVERSE-IT.pdf\">Read the press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valbiotis annonce le large succ\u00e8s de l\u2019\u00e9tude clinique de Phase II\/III internationale multicentrique REVERSE-IT sur TOTUM\u202263 qui d\u00e9montre son efficacit\u00e9 sur le principal facteur de risque du diab\u00e8te de type 2.<\/p>\n","protected":false},"author":2,"featured_media":4252,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-4247","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"og:description\" content=\"Valbiotis annonce le large succ\u00e8s de l\u2019\u00e9tude clinique de Phase II\/III internationale multicentrique REVERSE-IT sur TOTUM\u202263 qui d\u00e9montre son efficacit\u00e9 sur le principal facteur de risque du diab\u00e8te de type 2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\" \/>\n<meta property=\"og:site_name\" content=\"Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T13:51:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T13:51:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anne Leprand-Bigay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Leprand-Bigay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\"},\"author\":{\"name\":\"Anne Leprand-Bigay\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270\"},\"headline\":\"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes.\",\"datePublished\":\"2023-05-23T13:51:26+00:00\",\"dateModified\":\"2023-05-23T13:51:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\"},\"wordCount\":201,\"image\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\",\"name\":\"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne\",\"isPartOf\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg\",\"datePublished\":\"2023-05-23T13:51:26+00:00\",\"dateModified\":\"2023-05-23T13:51:56+00:00\",\"author\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage\",\"url\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg\",\"contentUrl\":\"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg\",\"width\":2048,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.biopole-clermont.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/\",\"name\":\"Biop\u00f4le Clermont-Limagne\",\"description\":\"Technopole des sciences du vivant\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270\",\"name\":\"Anne Leprand-Bigay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"caption\":\"Anne Leprand-Bigay\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/","og_locale":"en_US","og_type":"article","og_title":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne","og_description":"Valbiotis annonce le large succ\u00e8s de l\u2019\u00e9tude clinique de Phase II\/III internationale multicentrique REVERSE-IT sur TOTUM\u202263 qui d\u00e9montre son efficacit\u00e9 sur le principal facteur de risque du diab\u00e8te de type 2.","og_url":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/","og_site_name":"Biop\u00f4le Clermont-Limagne","article_published_time":"2023-05-23T13:51:26+00:00","article_modified_time":"2023-05-23T13:51:56+00:00","og_image":[{"width":2048,"height":1080,"url":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg","type":"image\/jpeg"}],"author":"Anne Leprand-Bigay","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Anne Leprand-Bigay","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#article","isPartOf":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/"},"author":{"name":"Anne Leprand-Bigay","@id":"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270"},"headline":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes.","datePublished":"2023-05-23T13:51:26+00:00","dateModified":"2023-05-23T13:51:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/"},"wordCount":201,"image":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/","url":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/","name":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes. - Biop\u00f4le Clermont-Limagne","isPartOf":{"@id":"https:\/\/www.biopole-clermont.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage"},"image":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg","datePublished":"2023-05-23T13:51:26+00:00","dateModified":"2023-05-23T13:51:56+00:00","author":{"@id":"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270"},"breadcrumb":{"@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#primaryimage","url":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg","contentUrl":"https:\/\/www.biopole-clermont.com\/wp-content\/uploads\/2023\/05\/VisuelRiomMicroscope_2705-scaled.jpg","width":2048,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.biopole-clermont.com\/en\/valbiotis-announces-the-large-success-of-the-reverse-it-international-multicentric-phase-ii-iii-clinical-study-on-totum63-proven-efficacy-on-the-main-risk-factor-of-developing-type-2-diabete\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.biopole-clermont.com\/en\/"},{"@type":"ListItem","position":2,"name":"Valbiotis announces the large success of the REVERSE-IT international multicentric Phase II\/III clinical study on TOTUM\u202263: proven efficacy on the main risk factor of developing type 2 diabetes."}]},{"@type":"WebSite","@id":"https:\/\/www.biopole-clermont.com\/en\/#website","url":"https:\/\/www.biopole-clermont.com\/en\/","name":"Biop\u00f4le Clermont-Limagne","description":"Technopole des sciences du vivant","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.biopole-clermont.com\/en\/#\/schema\/person\/afbaada0971acc53b6f886c83625f270","name":"Anne Leprand-Bigay","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","caption":"Anne Leprand-Bigay"}}]}},"_links":{"self":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/posts\/4247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/comments?post=4247"}],"version-history":[{"count":2,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/posts\/4247\/revisions"}],"predecessor-version":[{"id":4254,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/posts\/4247\/revisions\/4254"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/media\/4252"}],"wp:attachment":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/media?parent=4247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/categories?post=4247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/tags?post=4247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}